Malignant adrenal gland pheochromocytoma
MONDO:0006288A pheochromocytoma that metastasizes to other anatomic sites. Common sites of metastasis include lymph nodes, bones, liver, and lung. Morphologic features associated with malignant pheochromocytomas include: atypical mitotic figures, capsular and vascular invasion, tumor cell necrosis, and high mitotic activity.
Also known as: adrenal gland pheochromocytoma, malignant, malignant adrenal gland Chromaffinoma, malignant adrenal gland chromaffin neoplasm, malignant adrenal gland chromaffin paraganglioma, malignant adrenal gland chromaffin tumor, malignant adrenal gland chromaffin tumour, malignant adrenal gland paraganglioma, malignant adrenal gland pheochromocytoma
2828 clinical trials for this condition and its sub-types, 11 tagged with Malignant adrenal gland pheochromocytoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New combo shows promise for rare adrenal cancers
Disease control OngoingThis study tests whether adding olaparib to the standard chemotherapy temozolomide helps control advanced pheochromocytoma or paraganglioma—rare neuroendocrine tumors that have spread or can't be removed surgically. About 46 adults with these cancers will be randomly assigned to …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Rare cancer hope: immune drug shows promise in phase 2 trial
Disease control OngoingThis study tested a drug called pembrolizumab in 157 people with rare cancers that had spread or couldn't be removed. The drug works by helping the body's immune system attack the cancer. The main goal was to see how many patients were alive and their cancer hadn't grown after 27…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New hope for rare tumors: drug may slow cancer growth
Disease control OngoingThis study tests a drug called lanreotide in 10 people with advanced or metastatic paraganglioma or pheochromocytoma, rare tumors that release hormones. The goal is to see if lanreotide can slow tumor growth compared to before treatment. Participants receive injections every 4 we…
Phase 2 • Sponsor: Antonio Fojo • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC